IPEC-Americas Representatives Continue Discussions with FDA IID Working Group, Respond to Issues with Recent IID Updates and Prepare Comments to FR Docket on II
Discussions with FDA IID Working Group
Representatives from IPEC-Americas recently met with FDA’s Office of Generic Drugs (OGD) Inactive Ingredient Database (IID) Excipient Working Group on Thursday, July 30. The working group has been meeting regularly since December 2011 to address and improve FDA’s IID database. One of the main purposes of the team is to help resolve current issues with the FDA IID, which have ultimately impacted abbreviated new drug applications (ANDAs).